Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 685Carcinoma, Non-Small-Cell Lung 328Neoplasms 170Breast Neoplasms 166Lung Neoplasms 158Urinary Bladder Neoplasms 157Neoplasm Metastasis 140Cholangiocarcinoma 113Ovarian Neoplasms 106Biliary Tract Neoplasms 95Lymphoma, Large B-Cell, Diffuse 73Nasopharyngeal Carcinoma 71Lymphoma 66Sarcoma 63Recurrence 62Gallbladder Neoplasms 61Carcinoma, Transitional Cell 56Triple Negative Breast Neoplasms 54Hodgkin Disease 52Colorectal Neoplasms 49Lymphoma, Non-Hodgkin 48Fallopian Tube Neoplasms 48Adenocarcinoma 45Bile Duct Neoplasms 40Carcinoma, Ovarian Epithelial 31Non-Muscle Invasive Bladder Neoplasms 30Uterine Cervical Neoplasms 28Carcinoma 28Unspecified Adult Solid Tumor, Protocol Specific 27Adenocarcinoma of Lung 27

Interventions

Electroporation 2monomethyl auristatin E 1Oxaliplatin 1Gemcitabine 1Cryosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unresectable Pancreatic Cancer × Gemcitabine × Clear all
NCT02035072 2017-07-21

Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Completed
40 enrolled
Gastrointestinal

Unresectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡